Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0NO7V
|
|||
Drug Name |
PMID27828716-Compound-20
|
|||
Drug Type |
Small molecular drug
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H17FN4O2
|
|||
Canonical SMILES |
C1COCC=C1C2=NC(=CC=C2)NC(=O)NC3=C4C=CC=C(C4=NC=C3)F
|
|||
InChI |
1S/C20H17FN4O2/c21-15-4-1-3-14-17(7-10-22-19(14)15)24-20(26)25-18-6-2-5-16(23-18)13-8-11-27-12-9-13/h1-8,10H,9,11-12H2,(H2,22,23,24,25,26)
|
|||
InChIKey |
BYKSEVADXIBXTH-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1384424-60-5
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [1] |
Target's Patent Info | Glycogen synthase kinase-3 alpha (GSK-3A) | Target's Patent Info | [1] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Insulin/IGF pathway-protein kinase B signaling cascade | ||||
PDGF signaling pathway | ||||
Ras Pathway | ||||
Pathway Interaction Database | Degradation of beta catenin | |||
Canonical Wnt signaling pathway | ||||
FOXM1 transcription factor network | ||||
Class I PI3K signaling events mediated by Akt | ||||
Reactome | AKT phosphorylates targets in the cytosol | |||
XBP1(S) activates chaperone genes | ||||
Constitutive Signaling by AKT1 E17K in Cancer |
References | Top | |||
---|---|---|---|---|
REF 1 | Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.